NCT04904406View on ClinicalTrials.gov

Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 22, 2020

Primary Completion Date

December 1, 2023

Study Completion Date

December 1, 2023

Conditions

HivHIV InfectionsHIV CardiomyopathyWeight Change, BodyHIV LipodystrophyCardiovascular Diseases

Interventions

DRUG

Dolutegravir / Lamivudine Oral Tablet

Discontinuing abacavir by switching from three-drug regimen with dolutegravir/abacavir/lamivudine to two-drug regimen with dolutegravir/lamivudine

Trial Locations (2)

2100

Copenhagen University Hospital - Rigshospitalet, Copenhagen

2650

Copenhagen University Hospital, Amager Hvidovre, Hvidovre

All Listed Sponsors

lead

Thomas Benfield

OTHER

NCT04904406 - Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals | Biotech Hunter | Biotech Hunter